2. Academic Validation
  3. Esketamine alleviates ferroptosis-mediated acute lung injury by modulating the HIF-1α/HO-1 pathway

Esketamine alleviates ferroptosis-mediated acute lung injury by modulating the HIF-1α/HO-1 pathway

  • Int Immunopharmacol. 2024 Dec 5;142(Pt A):113065. doi: 10.1016/j.intimp.2024.113065.
Jinye Shi 1,  Shuang Song 2,  Yajie Wang 3,  Kaixuan Wu 1,  Gui Liang 1,  Aizhong Wang 4,  Xiaotao Xu 5
Affiliations

Affiliations

  • 1 Department of Anesthesiology, Affiliated Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 200233, China.
  • 2 Department of Respiratory Medicine, Affiliated Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 200233, China.
  • 3 Reproductive Medicine Center, General Hospital of Ningxia Medical University, Key Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Ningxia Medical University, Yinchuan 750004, Ningxia, China.
  • 4 Department of Anesthesiology, Affiliated Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 200233, China. Electronic address: wangaz@sjtu.edu.cn.
  • 5 Department of Anesthesiology, Affiliated Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 200233, China. Electronic address: xuxiaotao08@163.com.
PMID: 39243557 DOI: 10.1016/j.intimp.2024.113065
Abstract

Background: Alveolar epithelial cell (AEC) Ferroptosis contributes to the progression of acute lung injury (ALI). Esketamine (ESK) is a new clinical sedative, anesthetic, and analgesic drug that has attracted substantial attention in mental health research because of its antidepressant effects. However, the effects of ESK on ferroptosis-mediated ALI remain unclear.

Objective: This study aimed to explore the protective effect of ESK on AEC Ferroptosis in ALI and its potential molecular mechanism in vivo and in vitro.

Methods: The antiferroptotic and anti-inflammatory effects of ESK were assessed in a mouse model of lipopolysaccharide (LPS)-induced ALI. In vitro, the epithelial cell lines MLE-12 and A549 were used to examine the underlying mechanism by which ESK regulates inflammation and Ferroptosis.

Results: ESK protected mice against LPS-induced ALI, significantly attenuated pathological changes in the lungs and decreased inflammation and Ferroptosis. In vitro, ESK inhibited LPS-induced inflammation and Ferroptosis in MLE-12 and A549 cells. Moreover, Ferroptosis mediated inflammation in LPS-induced ALI in vivo and in vitro, and ESK decreased the LPS-induced inflammatory response by suppressing Ferroptosis. ESK promoted the HIF-1α/HO-1 pathway in LPS-treated AECs and in the lung tissues of mice with LPS-induced ALI. Moreover, pretreatment with ESK and the HIF-1α stabilizer dimethyloxaloylglycine (DMOG) substantially attenuated lung injury and prevented changes in ferroptosis-related biochemical Indicators, including glutathione (GSH) depletion, malondialdehyde (MDA) production and Glutathione Peroxidase 4 (GPX4) downregulation, in untreated LPS-induced mice but not in LPS-induced mice treated with the HO-1 inhibitor zinc protoporphyrin (ZNPP). Similar effects were observed in vitro in HO-1 siRNA-transfected A549 cells after LPS incubation but not in control siRNA-transfected cells.

Conclusion: ESK can inhibit ferroptosis-mediated lipid peroxidation by increasing the expression of HIF-1α/HO-1 pathway, highlighting the potential of ESK to treat LPS-induced ALI.

Keywords

Acute lung injury; Alveolar epithelial cell; Esketamine; Ferroptosis.

Figures
Products
Inhibitors & Agonists
Other Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z